{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:55:40Z","timestamp":1789498540795,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Teva Branded Pharmaceutical Products R&D, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s40263-024-01102-2","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T07:02:04Z","timestamp":1719903724000},"page":"625-636","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial"],"prefix":"10.1007","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct03893825","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"John M.","family":"Kane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Eshet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Harary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orna","family":"Tohami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Elgart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Knebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Suett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli R.","family":"Franzenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Glen L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"4","key":"1102_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","volume":"4","author":"C Hjorth\u00f8j","year":"2017","unstructured":"Hjorth\u00f8j C, St\u00fcrup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295\u2013301.","journal-title":"Lancet Psychiatry"},{"key":"1102_CR2","doi-asserted-by":"publisher","first-page":"15067","DOI":"10.1038\/nrdp.2015.67","volume":"1","author":"RS Kahn","year":"2015","unstructured":"Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1102_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/wps.20994","volume":"21","author":"CU Correll","year":"2022","unstructured":"Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248\u201371.","journal-title":"World Psychiatry"},{"key":"1102_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/epirev\/mxn001","volume":"30","author":"J McGrath","year":"2008","unstructured":"McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67\u201376.","journal-title":"Epidemiol Rev"},{"issue":"1","key":"1102_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","volume":"64","author":"J Per\u00e4l\u00e4","year":"2007","unstructured":"Per\u00e4l\u00e4 J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isomets\u00e4 E, Pirkola S, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64(1):19\u201328.","journal-title":"Arch Gen Psychiatry"},{"key":"1102_CR6","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.15m01901","author":"JM Jerrell","year":"2016","unstructured":"Jerrell JM, McIntyre RS. Factors differentiating childhood-onset and adolescent-onset schizophrenia: a claims database study. Prim Care Companion CNS Disord. 2016. https:\/\/doi.org\/10.4088\/PCC.15m01901.","journal-title":"Prim Care Companion CNS Disord."},{"issue":"2","key":"1102_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/wps.20516","volume":"17","author":"CU Correll","year":"2018","unstructured":"Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149\u201360.","journal-title":"World Psychiatry"},{"key":"1102_CR8","doi-asserted-by":"crossref","unstructured":"Fountoulakis KN, Moeller HJ, Kasper S, Tamminga C, Yamawaki S, Kahn R, et al. The report of the joint WPA\/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. CNS Spectr. 2020;1\u201325","DOI":"10.1017\/S1092852920001546"},{"issue":"1","key":"1102_CR9","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2021.2246","volume":"64","author":"A Catalan","year":"2021","unstructured":"Catalan A, Richter A, Salazar de Pablo G, Vaquerizo-Serrano J, Mancebo G, Pedruzo B, et al. Proportion and predictors of remission and recovery in first-episode psychosis: systematic review and meta-analysis. Eur Psychiatry. 2021;64(1): e69.","journal-title":"Eur Psychiatry"},{"issue":"4","key":"1102_CR10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.31887\/DCNS.2014.16.4\/mcarbon","volume":"16","author":"M Carbon","year":"2014","unstructured":"Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014;16(4):505\u201324.","journal-title":"Dialogues Clin Neurosci"},{"issue":"2","key":"1102_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/schbul\/sbac103","volume":"49","author":"HG Hansen","year":"2023","unstructured":"Hansen HG, Speyer H, Starzer M, Albert N, Hjorth\u00f8j C, Eplov LF, et al. Clinical recovery among individuals with a first-episode schizophrenia an updated systematic review and meta-analysis. Schizophr Bull. 2023;49(2):297\u2013308.","journal-title":"Schizophr Bull"},{"issue":"6","key":"1102_CR12","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41386-018-0278-3","volume":"44","author":"H Takeuchi","year":"2019","unstructured":"Takeuchi H, Siu C, Remington G, Fervaha G, Zipursky RB, Foussias G, et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology. 2019;44(6):1036\u201342.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"1102_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S2215-0366(22)00015-3","volume":"9","author":"H Taipale","year":"2022","unstructured":"Taipale H, Tanskanen A, Correll CU, Tiihonen J. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study. Lancet Psychiatry. 2022;9(4):271\u20139.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"1102_CR14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S2215-0366(18)30124-X","volume":"5","author":"RB Zipursky","year":"2018","unstructured":"Zipursky RB, Agid O, Remington G. Improving outcomes in schizophrenia by preventing early relapses. Lancet Psychiatry. 2018;5(5):384\u20136.","journal-title":"Lancet Psychiatry"},{"key":"1102_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.695672","volume":"12","author":"D Lin","year":"2021","unstructured":"Lin D, Joshi K, Keenan A, Shepherd J, Bailey H, Berry M, et al. Associations between relapses and psychosocial outcomes in patients with schizophrenia in real-world settings in the United States. Front Psychiatry. 2021;12: 695672.","journal-title":"Front Psychiatry"},{"issue":"3","key":"1102_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","volume":"56","author":"D Robinson","year":"1999","unstructured":"Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241\u20137.","journal-title":"Arch Gen Psychiatry"},{"issue":"1\u20133","key":"1102_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.schres.2011.08.024","volume":"133","author":"R Bod\u00e9n","year":"2011","unstructured":"Bod\u00e9n R, Brandt L, Kieler H, Andersen M, Reutfors J. Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Res. 2011;133(1\u20133):36\u201341.","journal-title":"Schizophr Res"},{"issue":"3","key":"1102_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/wps.20060","volume":"12","author":"JM Kane","year":"2013","unstructured":"Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216\u201326.","journal-title":"World Psychiatry"},{"issue":"2","key":"1102_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13696998.2017.1379412","volume":"21","author":"M Greene","year":"2018","unstructured":"Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127\u201334.","journal-title":"J Med Econ"},{"issue":"5","key":"1102_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","volume":"8","author":"T Kishimoto","year":"2021","unstructured":"Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387\u2013404.","journal-title":"Lancet Psychiatry"},{"key":"1102_CR21","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2147\/PPA.S127623","volume":"11","author":"D Pilon","year":"2017","unstructured":"Pilon D, Joshi K, Tandon N, Lafeuille MH, Kamstra RL, Emond B, et al. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Patient Prefer Adherence. 2017;11:619\u201329.","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"1102_CR22","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","volume":"72","author":"KL Subotnik","year":"2015","unstructured":"Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiat. 2015;72(8):822\u20139.","journal-title":"JAMA Psychiat"},{"issue":"6","key":"1102_CR23","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1093\/schbul\/sbab063","volume":"47","author":"JM Rubio","year":"2021","unstructured":"Rubio JM, Taipale H, Tanskanen A, Correll CU, Kane JM, Tiihonen J. Long-term continuity of antipsychotic treatment for schizophrenia: a nationwide study. Schizophr Bull. 2021;47(6):1611\u201320.","journal-title":"Schizophr Bull"},{"issue":"6","key":"1102_CR24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","volume":"168","author":"J Tiihonen","year":"2011","unstructured":"Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603\u20139.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"1102_CR25","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","volume":"77","author":"JM Kane","year":"2020","unstructured":"Kane JM, Schooler NR, Marcy P, Correll CU, Achtyes ED, Gibbons RD, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiat. 2020;77(12):1217\u201324.","journal-title":"JAMA Psychiat"},{"issue":"4","key":"1102_CR26","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/eip.12868","volume":"14","author":"B Brown","year":"2020","unstructured":"Brown B, Turkoz I, Mancevski B, Mathews M. Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia. Early Interv Psychiatry. 2020;14(4):428\u201338.","journal-title":"Early Interv Psychiatry"},{"issue":"2","key":"1102_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/JCP.0b013e318167269d","volume":"28","author":"R Emsley","year":"2008","unstructured":"Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol. 2008;28(2):210\u20133.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1102_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2658","volume":"33","author":"P Girardi","year":"2018","unstructured":"Girardi P, Del Casale A, Rapinesi C, Kotzalidis GD, Splendori F, Verzura C, et al. Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate. Hum Psychopharmacol. 2018;33(3): e2658.","journal-title":"Hum Psychopharmacol"},{"issue":"8","key":"1102_CR29","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/14656566.2016.1174692","volume":"17","author":"L Hargarter","year":"2016","unstructured":"Hargarter L, Bergmans P, Cherubin P, Keim S, Conca A, Serrano-Blanco A, et al. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia. Expert Opin Pharmacother. 2016;17(8):1043\u201353.","journal-title":"Expert Opin Pharmacother"},{"issue":"1\u20133","key":"1102_CR30","first-page":"36","volume":"17","author":"T Ohnishi","year":"2020","unstructured":"Ohnishi T, Kobayashi H, Yamaoka T, Toma T, Imai K, Wakamatsu A, et al. The effects of paliperidone palmitate 1 month on the employment status and social functioning of patients with schizophrenia. Innov Clin Neurosci. 2020;17(1\u20133):36\u201344.","journal-title":"Innov Clin Neurosci."},{"issue":"1","key":"1102_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41537-019-0091-y","volume":"6","author":"L Phahladira","year":"2020","unstructured":"Phahladira L, Luckhoff HK, Asmal L, Kilian S, Scheffler F, Plessis SD, et al. Early recovery in the first 24 months of treatment in first-episode schizophrenia-spectrum disorders. NPJ Schizophr. 2020;6(1):2.","journal-title":"NPJ Schizophr"},{"issue":"3","key":"1102_CR32","doi-asserted-by":"publisher","first-page":"22m14544","DOI":"10.4088\/JCP.22m14544","volume":"84","author":"JM Kane","year":"2023","unstructured":"Kane JM, Mychaskiw MA, Lim S, Suett M, Tian M, Rubio JM. Treatment journey from diagnosis to the successful implementation of a long-acting injectable antipsychotic agent in young adults with schizophrenia. J Clin Psychiatry. 2023;84(3):22m14544.","journal-title":"J Clin Psychiatry"},{"key":"1102_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/1471-244X-13-340","volume":"13","author":"PM Llorca","year":"2013","unstructured":"Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13:340.","journal-title":"BMC Psychiatry"},{"issue":"8","key":"1102_CR34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s40263-016-0350-7","volume":"30","author":"E Parellada","year":"2016","unstructured":"Parellada E, Bioque M. Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia. CNS Drugs. 2016;30(8):689\u2013701.","journal-title":"CNS Drugs"},{"issue":"11","key":"1102_CR35","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s40263-021-00861-6","volume":"35","author":"J Kane","year":"2021","unstructured":"Kane J, McEvoy JP, Correll CU, Llorca PM. Controversies surrounding the use of long-acting injectable antipsychotic medications for the treatment of patients with schizophrenia. CNS Drugs. 2021;35(11):1189\u2013205.","journal-title":"CNS Drugs"},{"issue":"6","key":"1102_CR36","doi-asserted-by":"publisher","first-page":"684","DOI":"10.4088\/JCP.13m08946","volume":"76","author":"PJ Weiden","year":"2015","unstructured":"Weiden PJ, Roma RS, Velligan DI, Alphs L, DiChiara M, Davidson B. The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry. 2015;76(6):684\u201390.","journal-title":"J Clin Psychiatry"},{"issue":"suppl 3","key":"1102_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","volume":"77","author":"CU Correll","year":"2016","unstructured":"Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1\u201324.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"1102_CR38","volume":"12","author":"RD Rattehalli","year":"2016","unstructured":"Rattehalli RD, Zhao S, Li BG, Jayaram MB, Xia J, Sampson S. Risperidone versus placebo for schizophrenia. Cochrane Database Syst Rev. 2016;12(12): CD006918.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1102_CR39","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","volume":"160","author":"JM Kane","year":"2003","unstructured":"Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125\u201332.","journal-title":"Am J Psychiatry"},{"key":"1102_CR40","unstructured":"Indivior Inc. Perseris\u2122 (risperidone) for extended-release injectable suspension. North Chesterfield, VA; 2021."},{"key":"1102_CR41","unstructured":"Janssen Pharmaceutical, Inc. Risperdal Consta\u00ae (risperidone) long-acting injection. Titusville, NJ; 2021."},{"key":"1102_CR42","unstructured":"Teva Neuroscience, Inc. UZEDY\u2122 (risperidone) extended-release injectable suspension. Parsippany, NJ; 2023."},{"key":"1102_CR43","unstructured":"Shandong Luye Pharmaceutical Co., Ltd. RYKINDO\u00ae (risperidone extended-release injectable suspension for intramuscular [IM] use). Yantai, Shandong, China; 2023."},{"key":"1102_CR44","unstructured":"Janssen Pharmaceutical, Inc. Risperdal\u00ae (risperidone) tablets, for oral use; Risperdal\u00ae (risperidone) oral solution; Risperdal\u00ae M-TAB\u00ae (risperidone) orally disintegrating tablets. Titusville, NJ; 2022."},{"issue":"7","key":"1102_CR45","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/cpdd.1078","volume":"11","author":"I Perlstein","year":"2022","unstructured":"Perlstein I, Merenlender Wagner A, Gomeni R, Lamson M, Harary E, Spiegelstein O, et al. Population pharmacokinetic modeling and simulation of TV-46000: a long-acting injectable formulation of risperidone. Clin Pharmacol Drug Dev. 2022;11(7):865\u201377.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"12","key":"1102_CR46","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2215-0366(23)00288-2","volume":"10","author":"JM Kane","year":"2023","unstructured":"Kane JM, Harary E, Eshet R, Tohami O, Weiser M, Leucht S, et al. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. Lancet Psychiatry. 2023;10(12):934\u201343.","journal-title":"Lancet Psychiatry"},{"key":"1102_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-244X-11-21","volume":"11","author":"I Turkoz","year":"2011","unstructured":"Turkoz I, Bossie CA, Lindenmayer JP, Schooler N, Canuso CM. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. BMC Psychiatry. 2011;11:21.","journal-title":"BMC Psychiatry"},{"issue":"2","key":"1102_CR48","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/JCP.0000000000000479","volume":"36","author":"AF Nasser","year":"2016","unstructured":"Nasser AF, Henderson DC, Fava M, Fudala PJ, Twumasi-Ankrah P, Kouassi A, et al. Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. J Clin Psychopharmacol. 2016;36(2):130\u201340.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"1102_CR49","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/JCP.0000000000001076","volume":"39","author":"A Andorn","year":"2019","unstructured":"Andorn A, Graham J, Csernansky J, Newcomer JW, Shinde S, Muma G, et al. Monthly extended-release risperidone (RBP-7000) in the treatment of schizophrenia: results from the phase 3 program. J Clin Psychopharmacol. 2019;39(5):428\u201333.","journal-title":"J Clin Psychopharmacol"},{"key":"1102_CR50","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.schres.2021.11.030","volume":"239","author":"Y Filts","year":"2022","unstructured":"Filts Y, Litman RE, Mart\u00ednez J, Anta L, Naber D, Correll CU. Long-term efficacy and safety of once-monthly Risperidone ISM\u00ae in the treatment of schizophrenia: results from a 12-month open-label extension study. Schizophr Res. 2022;239:83\u201391.","journal-title":"Schizophr Res"},{"issue":"1","key":"1102_CR51","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1017\/S1461145711001076","volume":"15","author":"WW Fleischhacker","year":"2012","unstructured":"Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol. 2012;15(1):107\u201318.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"1102_CR52","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/pcn.12824","volume":"73","author":"S Gentile","year":"2019","unstructured":"Gentile S. Discontinuation rates during long-term, second-generation antipsychotic long-acting injection treatment: a systematic review. Psychiatry Clin Neurosci. 2019;73(5):216\u201330.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"5","key":"1102_CR53","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s12325-023-02455-8","volume":"40","author":"DG Robinson","year":"2023","unstructured":"Robinson DG, Suett M, Wilhelm A, Chaijale N, Franzenburg KR, Gandhi S, et al. Patient and healthcare professional preferences for characteristics of long-acting injectable antipsychotic agents for the treatment of schizophrenia. Adv Ther. 2023;40(5):2249\u201364.","journal-title":"Adv Ther"},{"key":"1102_CR54","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/175360","volume":"2014","author":"RP Rajkumar","year":"2014","unstructured":"Rajkumar RP. Prolactin and psychopathology in schizophrenia: a literature review and reappraisal. Schizophr Res Treatment. 2014;2014: 175360.","journal-title":"Schizophr Res Treatment."},{"key":"1102_CR55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.schres.2021.08.013","volume":"237","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Zhang C, Siafis S, Zhuo K, Zhu D, Wu H, et al. Prolactin levels influenced by antipsychotic drugs in schizophrenia: a systematic review and network meta-analysis. Schizophr Res. 2021;237:20\u20135.","journal-title":"Schizophr Res"},{"issue":"1","key":"1102_CR56","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41537-021-00192-x","volume":"8","author":"CU Correll","year":"2022","unstructured":"Correll CU, Martin A, Patel C, Benson C, Goulding R, Kern-Sliwa J, et al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia (Heidelb). 2022;8(1):5.","journal-title":"Schizophrenia (Heidelb)."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01102-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01102-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01102-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T07:22:26Z","timestamp":1721287346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01102-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1102"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01102-2","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"6 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Teva Branded Pharmaceutical Products R&D, Inc. The sponsor participated in the design and conduct of the study and in the collection, management, analysis, and interpretation of the data and funded the preparation of the manuscript. All authors, including those affiliated with the sponsor, fulfilled all authorship criteria and participated in the review and approval of the manuscript and in the decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J.M.K. has been a consultant for or received honoraria from Alkermes, Boehringer Ingelheim, Cerevel, Click Therapuetics, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest (Allergan), Genentech, HLS Therapuetics, Intra-Cellular Therapies, Janssen, Johnson & Johnson, Karuna Therapeutics, LB Pharmaceuticals, Lundbeck, Lyndra Therapeutics, Merck, Neurocrine Biosciences, Newron, Otsuka, Pierre Fabre, Reviva Pharmaceuticals, Roche, Saladax Biomedical, Sunovion, Takeda, and Teva Pharmaceuticals; has received grant support from Otsuka, Lundbeck, and Janssen; and is a shareholder of Cerevel, Health Rhythms, LB Pharmaceuticals, and Vanguard Research Group. R.E., E.H., O.T., A.E., H.K., K.R.F., G.L.D., and N.S. are employees or stockholders, or both, of Teva Pharmaceuticals. M.S. is an employee and stockholder of Teva UK. C.U.C. has been a consultant for or has received honoraria from AbbVie, Acadia Pharmaceuticals, Alkermes, Allergan, Angelini Pharma, Aristo Pharma, Biogen, Boehringer Ingelheim, Cardio Diagnostics, Cerevel Therapeutics, CNX Therapeutics, COMPASS Pathways, Darnitsa, Denovo Biopharma, Gedeon Richter, Hikma, Holmusk, Intra-Cellular Therapies, Janssen, Johnson & Johnson, Karuna Therapeutics, LB Pharmaceuticals, Laboratorios Farmac\u00e9uticos ROVI, Lundbeck, MedAvante-ProPhase, MedinCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine Biosciences, Neurelis, Newron Pharmaceuticals, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati,\u00a0Relmada, Reviva, Sunovion, Supernus Pharmaceuticals, Takeda, Teva Pharmaceuticals, and Viatris; has provided expert testimony for Janssen and Otsuka and served on data safety monitoring boards or advisory boards for COMPASS Pathways, Denovo Biopharma, Laboratorios Farmac\u00e9uticos ROVI, Lundbeck, Relmada, Reviva, Sage Therapeutics, Supernus Pharmaceuticals, Tolmar, and Teva Pharmaceuticals; has received grant support from Janssen and Takeda and received royalties from UpToDate; serves on the board of directors for the American Society of Clinical Psychopharmacology; and is a stock option shareholder of Cardio Diagnostics, Mindpax, LB Pharmaceuticals, PsiloSterics, and Quantic Group.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The datasets used and\/or analyzed for the study described in this manuscript are available upon reasonable request. Qualified researchers may request access to patient-level data and related study documents including the study protocol and the statistical analysis plan. Patient-level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please visit\n                      \n                      to make your request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The protocol and subsequent amendments were approved before the start of the study by independent ethics committees (IECs)\/institutional review boards (IRBs) according to national or local regulations. IEC\/IRB organizations and approval numbers for the study include the following: Western IRB (20180568), Western IRB and WCG (ICO1-18-072), Copernicus Group (20190551), and Republic of Bulgaria\/Ethics Committee for Clinical Trials (KEMI\/CT-0412). This study was conducted in full accordance with the International Council for Harmonisation Good Clinical Practice Consolidated Guideline (E6) and any applicable national and local laws and regulations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Patients provided informed consent or assent, as applicable, at screening, before any study-related procedures or assessments were performed.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"J.M.K., R.E., E.H., O.T., and N.S. conceived and designed the study. J.M.K., R.E., E.H., O.T., A.E., H.K., N.S., M.S., K.R.F., G.L.D., and C.U.C. acquired, analyzed, and interpreted the data. R.E., E.H., O.T., A.E., H.K., N.S., G.L.D., and C.U.C. verified the data. J.M.K., R.E., E.H., O.T., A.E., H.K., N.S., M.S., K.R.F., G.L.D., and C.U.C. accessed the data. J.M.K., R.E., E.H., O.T., A.E., H.K., N.S., M.S., K.R.F., G.L.D., and C.U.C. drafted the manuscript. J.M.K., R.E., E.H., O.T., A.E., H.K., N.S., M.S., K.R.F., G.L.D., and C.U.C. critically revised the manuscript for important intellectual content. N.S. did the statistical analysis. G.L.D. provided administrative, technical, or material support. J.M.K., R.E., E.H., O.T., A.E., H.K., N.S., M.S., K.R.F., G.L.D., and C.U.C. approved the final submitted version and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}